feedback

Course Director

Barbara Burtness
Barbara Burtness

Professor of Medicine
Yale University School of Medicine
Co-Leader, Developmental Therapeutics Program
Director, Head and Neck Cancer Disease-Aligned Research Team
Yale Cancer Center
New Haven, Connecticut

Faculty

Ranee Mehra
Ranee Mehra

Professor of Medicine
Director of Head and Neck Medical Oncology
Experimental Therapeutics Research Program
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine
Baltimore, Maryland

Andrew Sharabi
Andrew Sharabi, MD, PhD

Assistant Professor of Radiation Medicine
Director, Radiation Medicine Core Facility
Department of Radiation Medicine and Applied Sciences
UC San Diego Health
Scientific Advisor, San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Accredited by

Medical Learning Institute, Inc.

Activity Description

In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (HNC). During this activity, the experts also explore several practical issues arising from the integration of immunotherapy into practice, including the selection of immunotherapy as upfront treatment, management of immune-related events, the use of immune-based multimodal therapy, and referral of patients with resectable or locally advanced disease for clinical trials.

Target Audience

The activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, and other clinicians involved in the management of patients with head and neck cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite updated evidence on immune checkpoint inhibitors in squamous cell carcinoma of the head and neck across treatment settings and patient populations
  • Select single-agent and immune-based combination regimens for the management of patients with recurrent/metastatic head and neck cancer, including as upfront treatment or after progression on platinum chemotherapy
  • Summarize the clinical potential of immunotherapy as part of multimodal care in the locally advanced or resectable head and neck cancer settings, including in the context of a clinical trial testing combinations of checkpoint inhibitors with surgery and/or radiation
  • Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities

Providership, Credit, and Support


This CME activity is jointly provided by Medical Learning Institute, Inc., the Head and Neck Cancer Alliance, and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc., the Head and Neck Cancer Alliance, and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Chair
Barbara Burtness, MD
Professor of Medicine
Yale University School of Medicine
Co-Leader, Developmental Therapeutics Program
Director, Head and Neck Cancer Disease-Aligned Research Team
Yale Cancer Center
New Haven, Connecticut

Barbara Burtness, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aduro Biotech; Alligator Bioscience AB; ALX Oncology; Celgene Corporation; Cue Biopharma, Inc.; Debiopharm; GlaxoSmithKline; Maverick Therapeutics; Merck & Co., Inc.; Nanobiotix; Oncolys BioPharma Inc.; and Rakuten Medical Inc.
Grant/Research Support from Merck & Co., Inc.
Data Safety Monitoring Board for Kura Oncology, Inc.

Faculty
Ranee Mehra, MD
Professor of Medicine
Director of Head and Neck Medical Oncology
Experimental Therapeutics Research Program
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine
Baltimore, Maryland

Ranee Mehra, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca and Merck & Co., Inc.
Honorarium from Bayer.

Andrew Sharabi, MD, PhD
Assistant Professor of Radiation Medicine
Director, Radiation Medicine Core Facility
Department of Radiation Medicine and Applied Sciences
UC San Diego Health
Scientific Advisor, San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Andrew Sharabi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca and Jounce Therapeutics, Inc.
Grant/Research Support from Pfizer, Inc. and Varian Medical Systems, Inc.
Founder of Toragen, Inc.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, PeerView Institute for Medical Education, and the Head and Neck Cancer Alliance, joint providers, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Shaina Rozell, MD, MPH

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.